Verastem (VSTM) Target Price Reduced to $14 with 211% Upside

RBC Capital maintained its Outperform rating on Verastem Inc. (NASDAQ: VSTM) and reduced the target price from $15 to $14, suggesting an upside potential of over 211%. This decision aligns with the firm's broader earnings preview for the biotech sector, following a rally in June. Verastem recently reported positive preliminary results from its Phase 1/2 trial for VS-7375, targeting late-stage KRAS G12D-mutated tumors. This information is significant for investors as it highlights the company's potential amid a favorable sentiment in the biotech sector.